Results 211 to 220 of about 836,514 (259)
Some of the next articles are maybe not open access.

[Inhibitors of 5-lipoxygenase].

Ceska a Slovenska farmacie : casopis Ceske farmaceuticke spolecnosti a Slovenske farmaceuticke spolecnosti, 2002
Leukotrienes are powerful mediators of inflammation processes. Possibilities of their biosynthesis inhibition have been intensively studied during recent two decades aiming to develop new methods of therapy of various inflammatory diseases, particularly asthma. Biosynthesis of all leukotrienes is dependent on the production of the key intermediate LTA4.
M, Gápovský, M, Remko
openaire   +1 more source

Evaluation of the antioxidative properties of lipoxygenase inhibitors

Pharmacological Reports, 2012
Oxidative stress is a component of many pathological conditions including neurodegenerative diseases and inflammation. An important source of reactive oxygen species (ROS) are lipoxygenases (LOX) - enzymes responsible for the metabolism of arachidonic acid and other polyunsaturated fatty acids.
Grzegorz A, Czapski   +2 more
openaire   +2 more sources

5-Lipoxygenase Inhibitors for the Treatment of COPD

Chest, 2002
The potential for leukotrienes as mediators to target in the development of novel therapies for diseases such as COPD is underscored by their inflammatory behavior and the capacity of leukotriene receptor antagonists and synthesis inhibitors to reduce inflammatory responses when administered in vivo.
openaire   +2 more sources

Endogenous inhibitors of lipoxygenase

European Journal of Pharmacology, 1980
S A, Saeed, M, Drew, H O, Collier
openaire   +2 more sources

Inhibitors of the 5-Lipoxygenase Pathway in Atherosclerosis

Current Pharmaceutical Design, 2009
The inflammatory environment within the atherosclerotic lesion stimulates the 5-lipoxygenase pathway of arachidonic acid metabolism, leading to the biosynthesis of the potent lipid inflammatory mediators leukotrienes. The present review summarizes the components of this pathway; the enzymes 5-lipoxygenase (5-LO, ALOX5) with its activating protein, FLAP
openaire   +2 more sources

The Clinical Landscape of HDAC Inhibitors

Medical Epigenetics, 2021
Arasu Ganesan
exaly  

Therapeutics and DNA Methylation Inhibitors

Medical Epigenetics, 2021
Shyamala C Navada
exaly  

LIPOXYGENASE INHIBITORS

2021
JONG LING, COLLINS NATHAN, NG RAYMOND
openaire   +3 more sources

A lipoxygenase inhibitor.

1989
YOKOYAMA KAZUMASA   +5 more
openaire   +5 more sources

Home - About - Disclaimer - Privacy